Maintenance: On Tuesday, February 12, 2019, maintenance work on some network components is scheduled from 19:45-22:30 hrs. ZORA will not be available during this period.
Hammerman, P S; Sos, M L; Ramos, A H; Xu, C; Dutt, A; Zhou, W; Brace, L E; Woods, B A; Lin, W; Zhang, J; Deng, X; Lim, S M; Heynck, S; Peifer, M; Simard, J R; Lawrence, M S; Onofrio, R C; Salvesen, H B; Seidel, D; Zander, T; Heuckmann, J M; Soltermann, A; Moch, H; Koker, M; Leenders, F; Gabler, F; Querings, S; Ansén, S; Brambilla, E; Brambilla, C; Lorimier, P; Brustugun, O T; Helland, A; Petersen, I; Clement, J H; Groen, H; Timens, W; Sietsma, H; Stoelben, E; Wolf, J; Beer, D G; Tsao, M S; Hanna, M; Hatton, C; Eck, M J; Janne, P A; Johnson, B E; Winckler, W; Greulich, H; Bass, A J; Cho, J; Rauh, D; Gray, N S; Wong, K K; Haura, E B; Thomas, R K; Meyerson, M (2011). Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discovery, 1(1):78-89.
Carbone, D P; Ciernik, I F; Kelley, M J; Smith, M C; Nadaf, S; Kavanaugh, D; Maher, V E; Stipanov, M; Contois, D; Johnson, B E; Pendleton, C D; Seifert, Burkhardt; Carter, C; Read, E J; Greenblatt, J; Top, L E; Kelsey, M I; Minna, J D; Berzofsky, J A (2005). Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome. Journal of Clinical Oncology, 23(22):5099-5107.